Impact of the Control of Symptomatic Paroxysmal Atrial Fibrillation on Health-related Quality of Life

Overview

Journal Europace

Publisher Oxford University Press

Specialties Cardiology & Vascular Diseases
Physiology

Date 2010 Feb 16

PMID 20154349

Citations 11

Authors

Laurence Guedon-Moreau

Alessandro Capucci

Isabelle Denjoy

Caroline Claire Morgan

Antoine Perier

Alain Leplege

Salem Kacet

Affiliations

Soon will be listed here.

Abstract

Aims: Patients with atrial fibrillation (AF) consider the related symptoms disruptive to their quality of life (QoL). This study aimed to evaluate the impact of the control of symptomatic paroxysmal AF (PAF) on QoL.

Methods And Results: Patients with symptomatic PAF were treated for 48 weeks with open-label flecainide acetate controlled release (Flec CR). Quality of life was assessed by SF-36 and Atrial Fibrillation Severity Scale scores at baseline, Week 12 (W12), W24, and W48. Of the 229 treated patients, 217 were analysed for QoL (123 with controlled and 94 with uncontrolled symptomatic PAF at inclusion). The controlled group had a similar or better QoL (SF-36) at baseline compared with a reference population (significantly better for: physical functioning, bodily pain, and physical component). The uncontrolled group had an inferior QoL (significantly worse for: role physical, general health, vitality, role emotional, social functioning, mental health, and mental component). When treated with Flec CR, the controlled group baseline QoL scores were maintained and the uncontrolled group scores were improved to a level comparable to the controlled group scores. Safety findings reflect the known clinical safety profile of flecainide acetate.

Conclusion: In this study, patients with uncontrolled symptomatic PAF at baseline had an inferior QoL to those with controlled symptomatic PAF. Following treatment with controlled-release flecainide acetate, their QoL improved to a level comparable to controlled patients.

Citing Articles

Atrial fibrillation symptom reduction and improved quality of life following the hybrid convergent procedure: a CONVERGE trial subanalysis.

Gill J, Crossen K, Blauth C, Kerendi F, Oza S, Magnano A Ann Cardiothorac Surg. 2024; 13(2):155-164.

PMID: 38590997 PMC: 10998972. DOI: 10.21037/acs-2023-afm-15.

Quality of life among people with atrial fibrillation with and without diabetes: a comparison study.

Hall A, Mitchell A, Ashmore L, Holland C Br J Cardiol. 2022; 28(4):42.

PMID: 35747069 PMC: 9063699. DOI: 10.5837/bjc.2021.042.

Atrial fibrillation burden, episode duration and frequency in relation to quality of life in patients with implantable cardiac monitor.

Jansson V, Bergfeldt L, Schwieler J, Kenneback G, Rubulis A, Jensen S Int J Cardiol Heart Vasc. 2021; 34:100791.

PMID: 34036145 PMC: 8134989. DOI: 10.1016/j.ijcha.2021.100791.

Effect Of Catheter Ablation On Quality Of Life In Atrial Fibrillation.

Gonzalez J, Macle L, Deyell M, Bennett M, Dubuc M, Dyrda K J Atr Fibrillation. 2016; 6(6):1063.

PMID: 27957067 PMC: 5135244. DOI: 10.4022/jafib.1063.

Making better scar: Emerging approaches for modifying mechanical and electrical properties following infarction and ablation.

Holmes J, Laksman Z, Gepstein L Prog Biophys Mol Biol. 2015; 120(1-3):134-48.

PMID: 26615948 PMC: 4808348. DOI: 10.1016/j.pbiomolbio.2015.11.002.

References

Lonnerholm S, Blomstrom P, Nilsson L, Oxelbark S, Jideus L, Blomstrom-Lundqvist C . Effects of the maze operation on health-related quality of life in patients with atrial fibrillation. Circulation. 2000; 101(22):2607-11. DOI: 10.1161/01.cir.101.22.2607. View

Reynolds M, Lavelle T, Essebag V, Cohen D, Zimetbaum P . Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J. 2006; 152(6):1097-103. PMC: 1820843. DOI: 10.1016/j.ahj.2006.08.011. View

Bubien R, Plumb V, Kay G . Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation. 1996; 94(7):1585-91. DOI: 10.1161/01.cir.94.7.1585. View

Thrall G, Lane D, Carroll D, Lip G . Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006; 119(5):448.e1-19. DOI: 10.1016/j.amjmed.2005.10.057. View

Fuster V, Ryden L, Cannom D, Crijns H, Curtis A, Ellenbogen K . ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for.... Circulation. 2006; 114(7):e257-354. DOI: 10.1161/CIRCULATIONAHA.106.177292. View

Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers G . The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol. 2000; 36(4):1303-9. DOI: 10.1016/s0735-1097(00)00886-x. View

Tenneze L, Tarral E, Ducloux N, Funck-Brentano C . Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism. Clin Pharmacol Ther. 2002; 72(2):112-22. DOI: 10.1067/mcp.2002.125946. View

Van Gelder I, Hagens V, Bosker H, Kingma J, Kamp O, Kingma T . A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002; 347(23):1834-40. DOI: 10.1056/NEJMoa021375. View

Reynolds M, Ellis E, Zimetbaum P . Quality of life in atrial fibrillation: measurement tools and impact of interventions. J Cardiovasc Electrophysiol. 2008; 19(7):762-8. PMC: 2574796. DOI: 10.1111/j.1540-8167.2007.01091.x. View

10.

Paquette M, Roy D, Talajic M, Newman D, Couturier A, Yang C . Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol. 2000; 86(7):764-8. DOI: 10.1016/s0002-9149(00)01077-8. View

11.

Dorian P, Mangat I . Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation. Card Electrophysiol Rev. 2004; 7(3):276-9. DOI: 10.1023/B:CEPR.0000012395.33292.cd. View

12.

Hamer M, Blumenthal J, McCarthy E, PHILLIPS B, Pritchett E . Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am J Cardiol. 1994; 74(8):826-9. DOI: 10.1016/0002-9149(94)90448-0. View

13.

Pritchett E, Datorre S, Platt M, McCarville S, Hougham A . Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. J Am Coll Cardiol. 1991; 17(2):297-303. DOI: 10.1016/s0735-1097(10)80090-7. View

14.

Wyse D, Waldo A, DiMarco J, Domanski M, Rosenberg Y, Schron E . A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347(23):1825-33. DOI: 10.1056/NEJMoa021328. View

15.

Henthorn R, Waldo A, Anderson J, Gilbert E, Alpert B, Bhandari A . Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. Circulation. 1991; 83(1):119-25. DOI: 10.1161/01.cir.83.1.119. View

16.

Hagens V, Ranchor A, van Sonderen E, Bosker H, Kamp O, Tijssen J . Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004; 43(2):241-7. DOI: 10.1016/j.jacc.2003.08.037. View

17.

Chouty F, COUMEL P . Oral flecainide for prophylaxis of paroxysmal atrial fibrillation. Am J Cardiol. 1988; 62(6):35D-37D. DOI: 10.1016/0002-9149(88)90501-2. View

18.

Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P . Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol. 2003; 42(2):185-97. DOI: 10.1016/s0735-1097(03)00577-1. View

19.

Dorian P, Paquette M, Newman D, Green M, Connolly S, Talajic M . Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J. 2002; 143(6):984-90. DOI: 10.1067/mhj.2002.122518. View

20.

Singh B, Singh S, Reda D, Tang X, Lopez B, Harris C . Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005; 352(18):1861-72. DOI: 10.1056/NEJMoa041705. View